The Fortune 500 s fastest-growing pharmaceutical companies #aristo #pharma


Posted On Mar 19 2017 by

#pharmaceutical industry growth

#

These are the Fortune 500’s fastest-growing pharma companies

The pharmaceutical industry has been rocked in recent years by a confluence of patent expirations of blockbuster drugs, increasing competition from generics and new governmental and industry efforts to control costs the world over.

That s made growth prospects for many pharma companies a risky and uncertain proposition. Some have pursued growth via innovative (and expensive) new drugs, like Gilead Science s hepatitis C treatment, Sovaldi, which can cost $84,000 for a full course. Some (see: Actavis) have pursued an aggressive acquisition strategy, buying their way to growth and cutting costs along the way. Others, like Celgene, have opted to strike various alliances with biotechs that have promising products in the pipeline, to hedge their bets over the long-term.

Whichever route a pharma CEO chooses, opportunities to expand sales will likely increase in coming years as the global elderly population grows, chronic diseases become more prevalent, and consumers in emerging markets demand access to modern drugs. (To see which Fortune 500 companies have grown the fastest over the past year, visit our brand-new, sortable list and sort by Rev Change. )

Here are the fastest growing pharma companies in the Fortune 500, based on compounded 5-year revenue growth.

The pharmaceutical industry has been rocked in recent years by a confluence of patent expirations of blockbuster drugs, increasing competition from generics and new governmental and industry efforts to control costs the world over.

That s made growth prospects for many pharma companies a risky and uncertain proposition. Some have pursued growth via innovative (and expensive) new drugs, like Gilead Science s hepatitis C treatment, Sovaldi, which can cost $84,000 for a full course. Some (see: Actavis) have pursued an aggressive acquisition strategy, buying their way to growth and cutting costs along the way. Others, like Celgene, have opted to strike various alliances with biotechs that have promising products in the pipeline, to hedge their bets over the long-term.

Whichever route a pharma CEO chooses, opportunities to expand sales will likely increase in coming years as the global elderly population grows, chronic diseases become more prevalent, and consumers in emerging markets demand access to modern drugs. (To see which Fortune 500 companies have grown the fastest over the past year, visit our brand-new, sortable list and sort by Rev Change. )

Here are the fastest growing pharma companies in the Fortune 500, based on compounded 5-year revenue growth.

Time Inc. All rights reserved.

Fortune.com is a part of the Time.com network of sites.

2016 Time Inc. All rights reserved.

Fortune.com is a part of the Time.com network of sites.

2016 Time Inc. All rights reserved.

Fortune.com is a part of the Time.com network of sites.

Sign In

Want the Full Story?

Get


Last Updated on: March 19th, 2017 at 5:36 pm, by


Written by admin


Leave a Reply

Your email address will not be published. Required fields are marked *